1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-W988549
    Zindotrine
    Inhibitor
    Zindotrine (MDL-257) is an orally active bronchodilator. Zindotrine is a cGMP phosphodiesterase (PDE) inhibitor. Zindotrine can counteract bronchospasm caused by histamine. Zindotrine can be used to study reversible airflow obstruction, such as asthma.
    Zindotrine
  • HY-A0027A
    Fenspiride
    Inhibitor
    Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC50 values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases.
    Fenspiride
  • HY-B0204B
    (-)-Pimobendan
    Control
    (-)-Pimobedan is an isomer of pimobedan. It has the property of stereoselective partitioning or distribution into erythrocytes. The clearance of (-)-pimobedan from erythrocytes is significantly lower than that of (+)-pimobedan, which is entirely due to its stereoselective distribution into erythrocytes. This stereoselective property of (-)-pimobedan may explain the phenomenon previously reported that it produces a 1.5-fold greater contractile force than the (+)-isomer in detergent-treated myocardial specimens of guinea pigs and dogs. These properties suggest that (-)-pimobedan may have unique advantages in terms of in vivo distribution and pharmacological action, which may have important implications for its clinical use.
    (-)-Pimobendan
  • HY-19038
    Y-20487
    Y-20487 is a cardiotonic agent. Y-20487 can induce cyclic AMP accumulation and exhibit positive inotropy.
    Y-20487
  • HY-173290
    PDE4D inhibitor 1
    Inhibitor
    PDE4-IN-1 is a PDE4 inhibitor with high potency (IC50 : 8.6 nM) and selectivity over other PDE subtypes. PDE4-IN-1 inhibits the release of inflammatory cytokines and chemokines. PDE4-IN-1 greatly restores impaired cAMP-CREB signaling pathway. PDE4-IN-1 inhibits proliferation and promotes differentiation to reverse the formation of psoriasis.
    PDE4D inhibitor 1
  • HY-10030
    Mardepodect succinate
    Mardepodect succinate (PF-2545920 succinate) is a potent and specific phosphodiesterase 10A (PDE10A) inhibitor with potential activity in the treatment of schizophrenia. Mardepodect succinate has been further optimized to improve brain penetration and compound-like properties for use in schizophrenia research.
    Mardepodect succinate
  • HY-W587881
    Acetylvardenafil
    Inhibitor
    Acetylvardenafil is a new analog of Vardenafil (HY-B0442). The sulfonyl group in the structure of Acetylvardenafil is replaced by an acetyl group. Acetylvardenafil is a PDE-5 inhibitor that can be used in the study of erectile dysfunction (ED).
    Acetylvardenafil
  • HY-100615A
    R 80123
    Inhibitor ≥98.0%
    R 80123 is the Z-isomer of R 79595, is also a highly selective phosphodiesterase inhibitor.
    R 80123
  • HY-19586
    Albifylline
    Inhibitor
    Albifylline (A 81-3138; HWA-138) is a Xanthine (HY-W017389) derivate. Albifylline reduces the shock-induced leukocyte adhesions to the sinusoidal endothelium in the liver after hemorrhagic shock and improves microvascular blood flow in the liver.
    Albifylline
  • HY-144265
    PDE4-IN-5
    Inhibitor
    PDE4-IN-5 (compound 33a) is a potent and selective PDE4 inhibitor (IC50=3.1 nM). PDE4-IN-5 has favorable skin permeability and a well-characterized binding mechanism. Anti-psoriasis effect.
    PDE4-IN-5
  • HY-111477
    (E/Z)-Ensifentrine
    Inhibitor
    (E/Z)-Ensifentrine is a dual inhibitor of PDE3/4. (E/Z)-Ensifentrine reduces the inflammatory cells into the airways. (E/Z)-Ensifentrine has bronchodilatory and anti-inflammatory activities in vitro and in vivo model.
    (E/Z)-Ensifentrine
  • HY-13295S
    Vinpocetine-d5
    Inhibitor
    Vinpocetine-d5 is the deuterium labeled Vinpocetine. Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na+ channels. The IC50 value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders.
    Vinpocetine-d<sub>5</sub>
  • HY-116253
    JNJ-42396302
    Inhibitor
    JNJ-42396302 is a PDE10A inhibitor. JNJ-42396302 can be used for the study of infertility.
    JNJ-42396302
  • HY-124310
    PDE5-IN-6c
    PDE5-IN-6c is a potent and selective phosphodiesterase 5A1 (PDE5A1) inhibitor with the potential to inhibit Alzheimer's disease (AD). PDE5-IN-6c exhibits an excellent in vitro IC50 (0.056 nM), demonstrating its potent inhibitory activity. PDE5-IN-6c has improved water solubility, making it a more attractive drug candidate.
    PDE5-IN-6c
  • HY-N17247
    Mesembranol
    Inhibitor
    Mesembranol ((-)-Mesembranol) is a mesembrine-type alkaloid and serotonin reuptake inhibitor. Mesembranol can be found in Sceletium tortuosum and exhibits phosphodiesterase 4 (PDE4) inhibition. Mesembranol contributes to the psychoactive properties of Sceletium tortuosum. Mesembranol can be used for the research of central nervous system-related conditions.
    Mesembranol
  • HY-139041
    Palmitoylcholine chloride
    Inhibitor 99.52%
    Palmitoylcholine chloride reduces membrane stress and reduces enzyme activity by Ca(2+)-dependent phosphatidylinositol phosphodiesterase (EC 3.1.4.10) hydrolysis of phosphatidylinositol monolayers.
    Palmitoylcholine chloride
  • HY-182060
    PDE4B/D-IN-5
    Inhibitor
    PDE4B/D-IN-5 (Compound P32) is a peripherally restricted, oral active inhibitor of PDE4B and PDE4D with extremely low blood-brain barrier penetration, with IC50 values of 3.4 nM and 2.2 nM, respectively. PDE4B-IN-8 inhibits the production of TNF-α. PDE4B/D-IN-5 significantly reduces the Bax/Bcl2 ratio, and alleviates oxidative stress by decreasing MPO activity and NO levels. PDE4B/D-IN-5 exhibits anti-inflammatory, antioxidant, and anti-apoptotic activities. PDE4B/D-IN-5 can be used for the research of acute lung injury.
    PDE4B/D-IN-5
  • HY-162954
    SMQ-03-20
    Inhibitor
    SMQ-03-20 (compund 4g) is an orally bioavailable, brain-penetrant, selective and potent PDE11A4 inhibitor.
    SMQ-03-20
  • HY-123008R
    Reproterol hydrochloride (Standard)
    Inhibitor
    Reproterol (hydrochloride) (Standard) is the analytical standard of Reproterol (hydrochloride). This product is intended for research and analytical applications. Reproterol hydrochloride is a dual-acting beta2-adrenoceptor agonist and phosphodiesterase inhibitor. Reproterol hydrochloride is more potent than albuterol and feterol in stimulating cAMP production in human monocytes, demonstrating its potential in enhancing airway function. Furthermore, Reproterol significantly inhibited the production of LTB4, indicating its anti-inflammatory properties. Reproterol hydrochloride may have inhibitory effects in respiratory diseases such as asthma and COPD.
    Reproterol hydrochloride (Standard)
  • HY-179595
    GSK4394835A
    Inhibitor
    GSK4394835A is a reversible covalent inhibitor of PDE3B with a pIC50 of 6.2. GSK4394835A can be used for cardiovascular disease research.
    GSK4394835A
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.